Strongbridge Biopharma plc (NASDAQ:SBBP)’s share price dropped 8.3% during trading on Tuesday . The company traded as low as $3.21 and last traded at $3.32. Approximately 1,235,161 shares were traded during mid-day trading, an increase of 43% from the average daily volume of 862,767 shares. The stock had previously closed at $3.62.

SBBP has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Strongbridge Biopharma in a report on Thursday, January 7th. Zacks Investment Research raised shares of Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Wednesday, December 16th. Five equities research analysts have rated the stock with a buy rating, Strongbridge Biopharma presently has a consensus rating of “Buy” and an average target price of $6.30.

The company has a market cap of $223.25 million, a price-to-earnings ratio of -3.80 and a beta of 1.91. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.51 and a quick ratio of 4.45. The firm’s fifty day moving average price is $3.03 and its 200-day moving average price is $2.78.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new stake in shares of Strongbridge Biopharma during the third quarter valued at about $27,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Strongbridge Biopharma in the 4th quarter valued at approximately $28,000. Credit Suisse AG purchased a new stake in shares of Strongbridge Biopharma in the 4th quarter valued at approximately $30,000. Jane Street Group LLC purchased a new stake in shares of Strongbridge Biopharma in the 3rd quarter valued at approximately $44,000. Finally, American International Group Inc. lifted its position in shares of Strongbridge Biopharma by 20.5% in the 4th quarter. American International Group Inc. now owns 25,591 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 4,352 shares in the last quarter. 58.27% of the stock is owned by institutional investors.

About Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States.

Featured Article: How are institutional investors different from individual investors?

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with's FREE daily email newsletter.